Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro

30 Aug 2021

Abstract excerpt

, with effects comparable to the anti-M. abscessus effects of linezolid both extracellularly and intracellularly. Contezolid did not antagonize the most frequently used anti-M. abscessus drugs, and preexposure to contezolid did not induce drug resistance. These results provide a novel approach to treating M. abscessus infections.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Infectious Diseases and Mycology
Share to Mycobacterium research and diagnosis
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34460305
DOI: 10.1128/aac.00889-21

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In VitroPMID 34460305Read ↗

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosisSemantic proximity Read ↗

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosisSemantic proximity Read ↗

In vitro activities of contezolid (MRX-I) against drug-sensitive and drug-resistant Mycobacterium tuberculosisSemantic proximity Read ↗

Drug Degradation Caused by mce3R Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis.Semantic proximity Read ↗

Novel oxazolidinones harbor potent in vitro activity against the clinical isolates of multidrug-resistant Mycobacterium tuberculosis in ChinaSemantic proximity Read ↗

Drug degradation caused by <i>mce3R</i> mutations confers contezolid (MRX-I) resistance in <i>Mycobacterium tuberculosis</i>Semantic proximity Read ↗

<i>In Vitro</i> efficacy comparison of linezolid, tedizolid, sutezolid and delpazolid against rapid growing Mycobacteria isolated in Beijing, ChinaSemantic proximity Read ↗

Multicentre evaluation of in vitro activity of contezolid against drug-resistant Staphylococcus and Enterococcus.Semantic proximity Read ↗

Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessusSemantic proximity Read ↗

Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, ChinaSemantic proximity Read ↗

Pipeline of anti‐Mycobacterium abscessussmall molecules: Repurposable drugs and promising novel chemical entitiesSemantic proximity Read ↗

In Vitro Efficacy Comparison of Linezolid, Tedizolid, Sutezolid and Delpazolid Against Rapid Growing Mycobacteria Isolated in Beijing, ChinaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.